medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2008, Number 2

<< Back Next >>

Rev Mex Urol 2008; 68 (2)

Serum testosterone (t) modifies prostate-specific antigen (psa) in erectile dysfunction (ed) patients. A preliminary report

Pérez-Martínez C, Vargas-Díaz IB, Cisneros-Castolo M

Language: Spanish
References: 28
Page: 111-114
PDF size: 99.32 Kb.


ABSTRACT

Introduction and Objective: Age modifies testosterone (T) levels associated with erectile dysfunction (ED) and prostate-specific antigen (PSA). There are no regional reports on T and PSA levels in ED patients. The objective of this study is to demonstrate the relation between T and PSA serum levels in patients presenting with ED in a city of Chihuahua, Mexico.
Patients and Methods: Eighty-six case records of ED patients were reviewed and classified as follows: Hypogonadal Group (HG) 19 patients with a T level =/‹ 300 ng/dl; Eugonadal Group (NG) 67 patients with a T level › 300 ng/dl. Age, T and PSA were analyzed using SPSS 10.0 statistical software and a 95% Confidence Interval.
Results: The HG mean age was 51.26 years, SD± 11.15 and the NG mean age was 50.88 years, SD±10.3. Mean T serum levels were: HG 236.10ng/ dl, SD±42.10 and NG 486.16ng/dl, SD±142.16. Mean PSA levels were: HG 4.726ng/ml, SD±10.108 and NG 1.293ng/ml, SD±1.135.
Conclusions: The difference in T serum levels between the two groups in our series was statistically significant (P=0.000). The mean age between groups (P=0.894) was not statistically significant. The mean value for PSA serum level was higher in the HG (4.726ng/ml) than in the NG (1.293ng/ml) and the difference was statistically significant (P=0.007). These results suggest the necessity of prostate cancer rule-out diagnosis when a patient presents with low T levels.


REFERENCES

  1. Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR & Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998;159:441-3.

  2. Rhoden EL & Morgentaler A. Testosterone Replacement Therapy In Hypogonadal Men At High Risk For Prostate Cancer: Results Of 1 Year Of Treatment In Men With Prostatic Intraepithelial Neoplasia. J Urol 2003;170:2348-51.

  3. Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, Shariat S et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 2007;43:2669-77.

  4. Prehn RT. On the Prevention and Therapy of Prostate Cancer by Androgen Administration. Cancer Res 1999;59:4161-4164.

  5. Morales A, Heaton JP & Carson CC. Andropause: A misnomer for a true clinical entity. J Urol 2000;163:705-12.

  6. Comhaire FH. Andropause: Hormone Replacement Therapy in the Ageing Male. Eur Urol 2000;38: 655-662.

  7. Traish AM & Kim N. Weapons of penile smooth muscle destruction: androgen deficiency promotes accumulation of adipocytes in the corpus cavernosum. Aging Male 2005;8:141-46.

  8. Morales A, Tenover JL. Androgen deficiency in the aging male: when, who, and how to investigate and treat. Urol Clin North Am 2002;29(4):975-82.

  9. Moncada I. Testosterone and men’s quality of life. Aging Male 2006;9(4):189-93.

  10. Guay AT. Testosterone and erectile physiology. Aging Male, 2006; 9(4):201-206.

  11. Pérez-Martínez C, Vargas-Díaz IB, Uribe-Arcila JF, Szemat R, Puigvert-Martínez AM, Fragas-Valdez R, Stewart J, Padron RS. Recomendaciones de la Sociedad Latinoamericana para el Estudio del Hombre Maduro (LASSAM) para la Prevención, Diagnóstico, Tratamiento y Monitoreo de la Andropausia o Hipogonadismo de Inicio Tardío. Urol Colomb, 2007;16:55-69.

  12. Pérez MC, Ureta SS, Vargas D IM, Fragas R, Torres LO, Silva H JM: El Síndrome de Andropausia: ¿qué es?, ¿cómo se trata?, ¿a quién? Guía práctica de diagnóstico y tratamiento. Rev Mex Urol 2003;63(2):65-74.

  13. Turhan S, Tulunay C, Gulec S, Ozdol C, Kilickap M, Altn T, Gerede M, Erol C. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis 2007;18(3):159-62.

  14. Heaton J P & Morales A. Testosterone values may alter the interpretation of serum PSA determination. J Urol 2004;171:167 (Abstract 628).

  15. Perez-Martinez C, Vargas-Diaz IB & Cisneros-Castolo M. Hypogonadism in Patients with Erectile Dysfunction (ED) Complains. Does the Age Modify The Testosterone (T) Blood Level? The Aging Male 2006; 9(1):50 (Abs. 179).

  16. Hoffmann MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-7.

  17. San Francisco IF, Regan MM, De Wolf WC, Olumi AF. Hypogonadism is associated with lower prostate specific antigen, later diagnosis and poorly differentiated prostate cancer: Implications for a lower screening threshold. J Urol 2004;171:167 (Abstract 629).

  18. San Francisco IF, Regan MM, De Wolf WC, Olumi AF. Low Age Adjusted Free Testosterone Levels Correlate with Poorly Differentiated Prostate Cancer. J Urol 2006;175:1341-1346.

  19. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006;50(5):935-939.

  20. Liverman CT, Blazer DG. Testosterone and Health Outcomes. In: Catharyn T. Liverman, Dan G. Blazer, Editors, Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academies Press, 2004. http://www.nap.edu/catalog/10852.html.

  21. Schatzl G, Brossner C, Schmidth S, Kugler W, Roehrich M, Treu T et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The prostate study group of Austrian Society of Urology. Urology 2000;55:397.

  22. Morales A, & Lunenfeld B. Standards, Guidelines and Recommendations of ISSAM. The Aging Male 2002; 5:74-86.

  23. Heracek J, Snajderova M, Sobotka V, Urban M, Kuncova J, Lukes M et al. The evaluation of prostate transrectal sonography, PSA, free PSA, and F/T PSA in term of two years testosterone substitution theraphy in Kallmann Syndrome. J Urol 2004;171:480 (abstract 1818).

  24. Kaufman JM & Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-22.

  25. Morales A. Testosterone and prostate health: debunking myths demands evidence, caution and good clinical judgment. Eur Urol 2006;50:895-897.

  26. David A. Gruenewald MD, Alvin M. Matsumoto MD. Testosterone Supplementation Therapy for Older Men: Potential Benefits and Risks. J Am Ger Soc, 2003;51:101-115.

  27. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113-120.

  28. Brand TC, Canby-Hagino E, Thompson IM. Testosterone replacement therapy and prostate cancer: a word of caution. Curr Urol Rep 2007;8:185-9.




2020     |     www.medigraphic.com